References
- TsaoHAtkinsMSoberAManagement of cutaneous melanomaN Engl J Med2004351998101215342808
- ApplebaumJReynoldsSKnispelruthJShapiroRIdentification of melanoma antigens that are immunogenic in humans and expressed in vivoJ Natl Cancer Inst19989021461499450575
- HodiFWell-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stageClin Cancer Res20061267367816467076
- LabradaMClavellMBebelaguaYDirect validation of NGcGM3 ganglioside as a new target for cancer immunotherapyExpert Opin Biol Ther201010215316220088712
- FernandezLEGabriMGuthmanMNGcGM3 ganglioside: a privileged target for cancer vaccinesClin Dev Immunol201081439721048926
- MarquinaGWakiHFernandezLEGangliosides expressed in human breast cancerCancer Res199615516551718912852
- CarrARodriguezEArangoMCCamachoROsorioMGabriMImmunotherapy of advanced breast cancer with heterophilic ganglioside (NeuGcGM3) cancer vaccineJ Clin Oncol20032161015102112637465
- OsorioMGraciaERodriguezEHeterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients. Results of a Phase Ib/IIa studyCancer Biol Ther20087448849518285705
- HodiFO’DaySMcDermottDImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med201036371172320525992
- KhanMAndrewsSIsmail-KhanROverall and progression-free survival in metastatic melanoma: analysis of a single-institution databaseCancer Control200613321121716885917
- Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0DCTD, NCI, NIH, DHHS3312003 (http://ctep.cancer.gov), Publish Date: August 9, 2006
- EisenhauerETherassePBogaertsJNew response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)Eur J Cancer20094522824719097774
- BlancoRRengifoERengifoCECedenoMFrometaMCarrAImmunohistochemical reactivity of the 14F7 monoclonal antibody raised against N-Glycolyl GM3 ganglioside in some benign and malignant skin neoplasmsISRN Dermatol201184890922363862
- de LeonJFernandezAMesaCClavelMFernandezLERole of tumor-associated N-gycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cellsCancer Immunol Immunother20065544345016208470
- EstevezFCarrASolorzanoLEnhancement of the immune response to poorly immnunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP)Vaccine20001819019710501249
- CumminsDLCumminsJMPantleHCutaneous malignant melanomaMayo Clin Proc200681450050716610570